Abstract: A data processing model builder precompiles a data processing model using a dependency tree and parameters provided by a provider of a product or service. New parameters can be provided in an intuitive way, without the need to understand computer program code, and a new data processing model can be compiled quickly and efficiently. The precompiled data processing model can then be deployed to provide personalized parameters for the product or service to end users almost instantaneously on request.

Abstract: Embodiments of the invention provide pharmaceutical compositions and methods for preventing and treating disease and promoting the health in subjects at risk of cardiovascular disease and/or kidney disease. Additional embodiments of the present invention provide compositions and methods useful for treating and preventing a cardiovascular disease or a kidney disease.

Abstract: Embodiments of the present invention are directed to improved medical saline compositions and methods of use thereof. Other embodiments of the invention concern nutritional compositions and methods that promote the health of the heart, kidneys, and vasculature in a subject at risk of developing disease.

Abstract: Embodiments of the invention provide pharmaceutical compositions and methods for preventing and treating disease and promoting the health in subjects at risk of cardiovascular disease and/or kidney disease. Additional embodiments of the present invention provide compositions and methods useful for treating and preventing a cardiovascular disease or a kidney disease.

Abstract: Embodiments of the present invention are directed to improved medical saline compositions and methods of use thereof. Other embodiments of the invention concern nutritional compositions and methods that promote the health of the heart, kidneys, and vasculature in a subject at risk of developing disease.

Abstract: A non-uniform light source is combined with a system including an integrating light pipe, a mask placed at the output of the light pipe, and a focusing element placed one focal length beyond the light pipe output at an angle appropriate for directing the light toward the illumination plane of the system. The purpose of the mask is to attenuate areas of the light pipe output that correspond to high irradiance regions at the illumination plane. Accordingly, this combination of optical components produces light with desired irradiance profile, including a substantially uniform irradiance profile, at the illumination plane.

Abstract: Two integrating light pipes are optically coupled to a focusing element to produce light with uniform irradiance and intensity profiles. The first ILP stage is used to receive spatially non-uniform light from a single or multi-color source and produce a uniform irradiance distribution while leaving the intensity distribution substantially unaltered. The focusing optical element swaps the irradiance and intensity distributions received from the output of the first ILP and feeds it to a second ILP stage which, in turn, completes the spatial homogenization of the light by transforming the non-uniform irradiance received from the focusing element into an output of uniform irradiance. As a result of this sequence of transformations, a homogeneous multi-color light output, both in intensity and irradiance, is produced.

Abstract: The present invention discloses a transgenic fly that expresses a carboxy terminal fragment of the human amyloid-? precursor protein (APP) and a double transgenic fly that expresses both the fragment of APP and tau protein. The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: A device is disclosed for transferring an organism from a donor container to a recipient container. The device comprises a transfer plate assembly comprising a first subassembly and a second subassembly. The transfer plate assembly positions donor containers and recipient containers in an inverted relationship so that the organism pass from the donor container to the recipient container. In addition, a method is presented for transferring a small organism from a donor container to a recipient container. The method includes engaging a donor container to a transfer plate assembly. The method discloses engaging a recipient container to the transfer plate assembly wherein the recipient container is in an inverted orientation to the donor container and rotating the transfer plate assembly so that the recipient container is positioned below the donor container which allows the small organism to be transferred.

Abstract: A reflector chamber, used to couple a light source to a downstream light-transport medium, includes a forward reflector which folds the light impinging upon it forward and a backward reflector that folds backwards the light received from the light source or the forward reflector. The two reflectors are judiciously shaped so as to maximize the energy density at the output aperture with an angle of emission within the numerical aperture of the downstream medium. The forward reflector is preferably shaped substantially flat and coplanar with the light source. The backward reflector is preferably a concave section. A diverging light reflector may be added to the output aperture of the coupler in order to increase its efficiency.

Abstract: An ILP comprises a rotationally symmetric surface in an outer structure serving as a spatial limiter and an inner optical surface that is rotationally asymmetric in cross-section disposed lengthwise within the outer structure. The inner surface acts as a conventional light-integrator and is designed to allow a portion of the homogenized light to spread toward the rotationally symmetric surface upon propagation. As a result, by the time the light reaches the end of the ILP, the entire circular area at its output facet is filled with uniform-irradiance light.

Abstract: Methods and pharmaceutical compositions are disclosed for treating neurological disorders, such as Huntington's disease or Alzheimer's disease. The methods involve the administration of a triarylmethane compound, such as clotrimazole, or a salt thereof.

Abstract: Two integrating light pipes are optically coupled to a focusing element to produce light with uniform irradiance and intensity profiles. The first ILP stage is used to receive spatially non-uniform light from a single or multi-color source and produce a uniform irradiance distribution while leaving the intensity distribution substantially unaltered. The focusing optical element swaps the irradiance and intensity distributions received from the output of the first ILP and feeds it to a second ILP stage which, in turn, completes the spatial homogenization of the light by transforming the non-uniform irradiance received from the focusing element into an output of uniform irradiance. As a result of this sequence of transformations, a homogeneous multi-color light output, both in intensity and irradiance, is produced.

Abstract: The present invention relates to a class of small molecule hydroxamic acid compounds capable of inhibiting histone deacetylases (HDACs). The present invention also relates to methods of preparation of hydroxamic acid HDAC inhibitor compounds of the invention, which are N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, and their incorporation into pharmaceutical compositions and methods of administration. The present invention also relates to N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, which may be prepared as a hydroxamic acid HDAC inhibitor compound library that can be utilized in screening methods known in the art.

Abstract: The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human A?42 peptide of human amyloid-? precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A?42Dutch peptide of human amyloid-? precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Italian mutant version of the human A?42 peptide of human amyloid-? precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A?42Italian peptide of human amyloid-? precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human A?42 peptide of human amyloid-? precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A?42Arctic peptide of human amyloid-? precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human A?42 peptide of human amyloid-? precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A?42Flemish peptide of human amyloid-? precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Iowa mutant version of the human A?42 peptide of human amyloid-? precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A?42Iowa peptide of human amyloid-? precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Italian mutant version of the human A?42 peptide of human amyloid-? precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A?42Italian peptide of human amyloid-? precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.